,2 Outcomes for advanced MCC have recently improved with the shift from chemotherapy to immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathways. The gene discussed is CD274; the disease is Merkel cell skin cancer.